Bucladesine

This classification denotes a phosphodiesterase inhibitor with the molecular formula C18H24N5O8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63X7MBT2LQ, chemically known as 16980-89-5 (sodium salt, monohydrate) but generally known as bucladesine, which bears US NIH Compound Identifier 9687. Bucladesine most often comes in base and sodium forms. European Medicines Agency schedules Bucladesine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05946MIG. The term BUCLADESINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules bucladesine in its Anatomical Therapeutic Chemical (ATC) Classification. BUCLADESINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bucladesine under HS 29349990 and SITC 51579. As of Q4 2014, BUCLADESINE remains the US FDA Preferred Term for this commodity. Bucladesine bears US NLM identifiers UMLS ID C0012054 and NCI Concept Code C83562. SMILES: P1(=O)(OC2C(OC(=O)CCC)C(OC2CO1)N1C2NCNC(NC(=O)CCC)C2NC1)O.